Thus, it is possible that the variability of UGT1A in lymphomas may result in a different catalytic efficacy of the glucuronidation system, determining diverse levels of bilirubin and outcomes of HD-MTX treatment in PCNSL. Here, UGT1A1 is linked to lymphoma.